1. Home
  2. STE vs INSM Comparison

STE vs INSM Comparison

Compare STE & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo STERIS plc (Ireland)

STE

STERIS plc (Ireland)

HOLD

Current Price

$222.30

Market Cap

21.7B

Sector

Health Care

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$95.56

Market Cap

22.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STE
INSM
Founded
1985
1988
Country
United States
United States
Employees
17937
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.7B
22.4B
IPO Year
2018
2000

Fundamental Metrics

Financial Performance
Metric
STE
INSM
Price
$222.30
$95.56
Analyst Decision
Buy
Strong Buy
Analyst Count
9
24
Target Price
★ $262.14
$197.00
AVG Volume (30 Days)
549.1K
★ 2.6M
Earning Date
11-04-2026
10-29-2026
Dividend Yield
★ 1.24%
N/A
EPS Growth
★ 27.90
N/A
EPS
★ 7.93
N/A
Revenue
★ $5,935,900,000.00
N/A
Revenue This Year
$7.35
$196.85
Revenue Next Year
$6.36
$61.71
P/E Ratio
$28.05
★ N/A
Revenue Growth
★ 8.73
N/A
52 Week Low
$195.14
$90.39
52 Week High
$269.44
$212.75

Technical Indicators

Market Signals
Indicator
STE
INSM
Relative Strength Index (RSI) 59.86 29.46
Support Level $216.22 $90.39
Resistance Level $227.10 $119.54
Average True Range (ATR) 4.39 3.84
MACD 1.98 -0.82
Stochastic Oscillator 74.13 8.96

Price Performance

Historical Comparison
STE
INSM

About STE STERIS plc (Ireland)

Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 20% from Applied Sterilization Technologies, or AST, and 10% from life sciences services after the divestment of its dental products business.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Share on Social Networks: